Bio-Path Investor Relations Material
Latest events
Status Update
Bio-Path
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Bio-Path Holdings Inc
Access all reports
Bio-Path Holdings Inc. is a biotechnology company focused on the development of RNAi-based therapies for cancer treatment. The company uses its proprietary DNAbilize® platform to design lipid-delivered RNAi therapeutics that target specific proteins involved in cancer cell survival and proliferation. Bio-Path’s lead programs focus on treating hematologic cancers such as leukemia and lymphoma. The company’s approach aims to provide innovative treatment options for patients with unmet medical needs in oncology. The company is headquartered in Bellaire, Texas, USA, and its shares are listed on the NASDAQ.
Latest articles
)
Global Doughmination: Breaking Down Domino's Pizza
Inside the rise of Domino's Pizza: how franchising, delivery control, and supply chain mastery built one of the world's most efficient food empires.
18 Jul 2025
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
Ticker symbol
BPTH
Country
🇺🇸 United States